Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

3SBio (TRSBF) Stock Price & Analysis

TRSBF Stock Chart & Stats

$1.72-$0.01(-0.29%)
At close: 4:00 PM EDT
$1.75$1.8$1.85$1.912 Oct20 Oct30 Oct
Day’s Range
$1.72 - $1.72
52-Week Range
$1.66 - $4.30
Previous Close
$1.73
Volume
125
Average Volume (3M)
875
Market Cap
$4.38B
Enterprise Value
$28.64B
Total Cash (Recent Filing)
$17.59B
Total Debt (Recent Filing)
$1.39B
Price to Earnings (P/E)
3.5
Beta
-1.68
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
0.07
Last Dividend Ex-Date
Jul 21, 2026
Dividend Yield
1.81%

Bulls Say, Bears Say

Bulls Say

Revenue Growth

The sharp 2025 revenue acceleration indicates stronger commercial traction across 3SBio’s marketed therapies and distribution channels. If the expanded sales base persists, it can provide operating scale, support investment in development, and strengthen the company’s position in nephrology and oncology.

Profitability

Exceptionally high 2025 margins show that the company converted revenue into earnings very efficiently. Strong profitability can fund research, commercialization, and balance-sheet investment internally, while creating resilience if the business maintains product access and pricing across its core therapeutic areas.

Balance Sheet And Cash Generation

Low leverage and strong cash conversion provide financial flexibility for a biopharmaceutical business that must fund research, development, and commercialization. Cash generation closely matching earnings also supports the quality of reported profits and reduces dependence on additional borrowing.

Bears Say

Earnings Sustainability

The sharp improvement in 2025 has not yet established a consistently demonstrated earnings pattern across the full period provided. Earlier volatility in growth and margins makes the durability of the latest profitability level an important fundamental consideration for the next several quarters.

Cash Flow Volatility

Prior periods of weaker cash conversion indicate that accounting earnings did not always translate into cash at the same rate. If that pattern returns, it could constrain internally funded investment and make reported profit less dependable as a measure of recurring financial strength.

Return Consistency

The large variation in return on equity suggests that capital productivity has not been consistently strong over time. A return profile dependent on the exceptional 2025 result would make future performance more sensitive to changes in margins, revenue growth, and the mix of marketed therapies.

3SBio News

TRSBF FAQ

What was 3SBio’s price range in the past 12 months?
3SBio lowest stock price was $1.66 and its highest was $4.30 in the past 12 months.
What is 3SBio’s market cap?
3SBio’s market cap is $4.38B.
When is 3SBio’s upcoming earnings report date?
3SBio’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 148 days.
How were 3SBio’s earnings last quarter?
3SBio released its earnings results on Aug 20, 2026. The company reported $0.066 earnings per share for the quarter, missing the consensus estimate of $0.095 by -$0.03.
Is 3SBio overvalued?
According to Wall Street analysts 3SBio’s price is currently Undervalued.
Does 3SBio pay dividends?
3SBio pays a Annually dividend of $0.032 which represents an annual dividend yield of 1.81%. See more information on 3SBio dividends here
What is 3SBio’s EPS estimate?
3SBio’s EPS estimate is 0.07.
How many shares outstanding does 3SBio have?
3SBio has 2,538,321,000 shares outstanding.
What happened to 3SBio’s price movement after its last earnings report?
3SBio reported an EPS of $0.066 in its last earnings report, missing expectations of $0.095. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of 3SBio?
Currently, no hedge funds are holding shares in TRSBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology